# Elite Technology-Transfer Dossier — P-01

**Generated:** 2026-08-26T05:28:02.189811+00:00
**Schema:** ELITE_TECHNOLOGY_TRANSFER_DOSSIER_v1
**Three axes:** T2-CONDITIONAL / READY_FOR_TECHNICAL_EVALUATION / UNCONTACTED
**Buyer truth:** A computationally verified P-01 technology (conditional on geometry/scope) with physical validation still outstanding.
**Not a patent court:** True

---

## 01 — Buyer Decision Card

━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
BUYER DECISION CARD
P-01
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━

**TECHNOLOGY**
P-01 — Multi-segment CSF shunt with Bayesian occlusion prediction and pre-emptive flow 

**WHY YOU MAY CARE**
A computationally verified P-01 technology (conditional on geometry/scope) with physical validation still outstanding.

**CURRENT EVIDENCE**
  Technical readiness: T2-CONDITIONAL
  Physical validation: PARTIAL
  Transfer posture: READY_FOR_TECHNICAL_EVALUATION

**WHAT IS NOT PROVEN**
  - Strict dual-invariant FALSIFIED (peak 22>20 mmHg)
  - 24h survival not achieved
  - FDA nozzle benchmark 72% disagreement (different geometry, not P-01's)

**STRONGEST ALTERNATIVE**
  Single-segment programmable valve (Medtronic Strata) — reactive, not predictive

**DECISIVE QUESTION**
  Whether multi-segment advantage survives a TRUE 3D multi-segment mesh (not flow-rate proxy). Implantable flow sensor doesn't exist commercially.

**COST TO ANSWER**
  $3-5K (ESTIMATED: COTS components)

**TIME**
  3-6 months (ESTIMATED)

**IF PASS**
  Advance to next development phase (see Development Plan)

**IF FAIL**
  Repair / redesign / terminate (see Failure Record)

**WHAT WE ARE ASKING YOU TO DO**
  LICENSE — reproduce computation (clone, run svMultiPhysics), then commission V0 bench prototype

**BUYER_ACTION_ID**
  P01-EXP-001

━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━

---

## 02 — Executive Technology Brief

# Executive Technology Brief — P-01

**Reading time target:** 2 minutes

## Problem
Catheter obstruction causes 30-50% of shunt failures. $35-50K per revision surgery (SOURCE_DERIVED: HCUP/AHRQ).

## Technology
Multi-segment CSF shunt with Bayesian occlusion prediction and pre-emptive flow redistribution maintaining dual safety invariants

## Potential Advantage
Whether multi-segment advantage survives a TRUE 3D multi-segment mesh (not flow-rate proxy). Implantable flow sensor doesn't exist commercially.

## Evidence Summary
- Technical readiness: T2-CONDITIONAL
- Transfer posture: READY_FOR_TECHNICAL_EVALUATION
- T2-CONDITIONAL — 3 modelled claims, 1 computationally supported

## Remaining Risk
Whether multi-segment advantage survives a TRUE 3D multi-segment mesh (not flow-rate proxy). Implantable flow sensor doesn't exist commercially.

## Next Action
LICENSE — reproduce computation (clone, run svMultiPhysics), then commission V0 bench prototype

---
*This is an elite technology-transfer dossier. Every claim traces to evidence. Every uncertainty is explicit. See full dossier for details.*


---

## 03 — Customer / Industrial Problem

- **Exact problem:** Catheter obstruction causes 30-50% of shunt failures. $35-50K per revision surgery (SOURCE_DERIVED: HCUP/AHRQ).
- **Affected users:** Shunt OEM (Medtronic, Integra, Sophysa)
- **Frequency:** BUYER_DILIGENCE_REQUIRED — clinical incidence data not in package
- **Current cost:** BUYER_DILIGENCE_REQUIRED — economic model not yet sourced
- **Current workaround:** Single-segment programmable valve (Medtronic Strata) — reactive, not predictive
- **Incumbent solutions:** ['Single-segment programmable valve (Medtronic Strata) — reactive, not predictive']
- **Why problem remains unsolved:** Whether multi-segment advantage survives a TRUE 3D multi-segment mesh (not flow-rate proxy). Implantable flow sensor doesn't exist commercially.

---

## 04 — Technology Description

- **Mechanism:** Multi-segment CSF shunt with Bayesian occlusion prediction and pre-emptive flow redistribution maintaining dual safety invariants
- **Architecture:** SEE mechanism field — full architecture requires technical diligence
- **Components:** BUYER_DILIGENCE_REQUIRED
- **Inputs:** BUYER_DILIGENCE_REQUIRED
- **Outputs:** BUYER_DILIGENCE_REQUIRED
- **Operating conditions:** BUYER_DILIGENCE_REQUIRED
- **Diagrams:** NOT_GENERATED — buyer diligence team to request
- **Key equations:** SEE provenance artifacts (model scripts)
- **Dependencies:** BUYER_DILIGENCE_REQUIRED
- **Implementation assumptions:**
  - Strict dual-invariant FALSIFIED (peak 22>20 mmHg)
  - 24h survival not achieved
  - FDA nozzle benchmark 72% disagreement (different geometry, not P-01's)

---

## 05 — What Is Actually New?

- **Known prior approaches:** ['Single-segment programmable valve (Medtronic Strata) — reactive, not predictive']
- **Limitation of prior:** Whether multi-segment advantage survives a TRUE 3D multi-segment mesh (not flow-rate proxy). Implantable flow sensor doesn't exist commercially.
- **Our mechanism:** Multi-segment CSF shunt with Bayesian occlusion prediction and pre-emptive flow redistribution maintaining dual safety invariants
- **Difference:** Differentiation hypothesis: Whether multi-segment advantage survives a TRUE 3D multi-segment mesh (not flow-rate proxy). Implantable flow sensor doesn't exist commercially.
- **Expected advantage:** Whether multi-segment advantage survives a TRUE 3D multi-segment mesh (not flow-rate proxy). Implantable flow sensor doesn't exist commercially.
- **Note:** Do not say 'novel technology.' Say what existing systems do, what breaks, and how this mechanism changes the failure mode.

---

## 06 — Competitive Alternatives

| Approach | Strength | Weakness | Evidence | Why buyer might choose us |
|----------|----------|---------|----------|---------------------------|
| Single-segment programmable valve (Medtronic Strata) — reactive, not predictive | Established clinical track record | BUYER_DILIGENCE_REQUIRED | Published clinical literature | Whether multi-segment advantage survives a TRUE 3D multi-seg |
| P-01 — Multi-segment CSF shunt with Bayesian occlusion prediction a | SEE evidence ledger | Strict dual-invariant FALSIFIED (peak 22>20 mmHg) | T2-CONDITIONAL — see evidence ledger | A computationally verified P-01 technology (conditional on g |

**Where we lose:**
  - Strict dual-invariant FALSIFIED (peak 22>20 mmHg)
  - 24h survival not achieved
  - FDA nozzle benchmark 72% disagreement (different geometry, not P-01's)

*An elite package tells the buyer where the technology currently loses. This is more credible than claiming superiority.*

---

## 07 — Evidence & Validation Ledger

### COMPUTATIONALLY_SUPPORTED
- **Claim:** T2-CONDITIONAL. svMultiPhysics 3D Navier-Stokes verified 1D model within 16% on candidate geometry (flow-rate proxy). 225 ablations confirmed rate-lim
  - Method: external computational solver (svMultiPhysics)
  - Source: R318/p01_svmp_candidate/ + R310/p01_ttp/ + TTP_PACKAGES/P-01_PROTOTYPE/
  - Limitation: computational only — no physical validation
  - Confidence: high (solver verified)

### MODELLED
- **Claim:** 30% revision rate reduction
  - Method: internal computational model
  - Source: R318/p01_svmp_candidate/ + R310/p01_ttp/ + TTP_PACKAGES/P-01_PROTOTYPE/
  - Limitation: model prediction — not experimentally verified
  - Confidence: model-derived
- **Claim:** $124M/yr value
  - Method: internal computational model
  - Source: R318/p01_svmp_candidate/ + R310/p01_ttp/ + TTP_PACKAGES/P-01_PROTOTYPE/
  - Limitation: model prediction — not experimentally verified
  - Confidence: model-derived
- **Claim:** 24h survival (both designs fail ~14h)
  - Method: internal computational model
  - Source: R318/p01_svmp_candidate/ + R310/p01_ttp/ + TTP_PACKAGES/P-01_PROTOTYPE/
  - Limitation: model prediction — not experimentally verified
  - Confidence: model-derived

### ASSUMED
- **Claim:** FAILED ASSUMPTION: Strict dual-invariant FALSIFIED (peak 22>20 mmHg)
  - Method: internal computational model
  - Source: R318/p01_svmp_candidate/ + R310/p01_ttp/ + TTP_PACKAGES/P-01_PROTOTYPE/
  - Limitation: this assumption broke — buyer must not rely on it
  - Confidence: high (falsified)
- **Claim:** FAILED ASSUMPTION: 24h survival not achieved
  - Method: internal computational model
  - Source: R318/p01_svmp_candidate/ + R310/p01_ttp/ + TTP_PACKAGES/P-01_PROTOTYPE/
  - Limitation: this assumption broke — buyer must not rely on it
  - Confidence: high (falsified)
- **Claim:** FAILED ASSUMPTION: FDA nozzle benchmark 72% disagreement (different geometry, not P-01's)
  - Method: internal computational model
  - Source: R318/p01_svmp_candidate/ + R310/p01_ttp/ + TTP_PACKAGES/P-01_PROTOTYPE/
  - Limitation: this assumption broke — buyer must not rely on it
  - Confidence: high (falsified)

---

## 08 — Technical Readiness & Risk

- **Technical readiness:** T2-CONDITIONAL
- **Physical validation:** PARTIAL
- **Manufacturing readiness:** UNKNOWN
- **Integration readiness:** UNKNOWN
- **Regulatory readiness:** UNKNOWN

### Risk Register
| Risk | Probability | Impact | Evidence | Mitigation | Experiment |
|------|------------|--------|----------|------------|------------|
| Mechanism does not survive physical validation | LOW | HIGH | No physical validation performed | Decisive experiment (see Section 10/11) | V0 bench prototype: 4-segment shunt + CO |
| Manufacturing tolerances exceed design envelope | UNKNOWN | HIGH | No manufacturing tolerance study | BUYER_DILIGENCE_REQUIRED | Manufacturing feasibility study |
| Regulatory pathway more complex than estimated | UNKNOWN | MEDIUM | PMA required (Class III implantable) | Regulatory consultant review | Pre-submission meeting with FDA |

---

## 09 — Failure & Falsification Record

- **Failed hypotheses:** ['Strict dual-invariant FALSIFIED (peak 22>20 mmHg)', '24h survival not achieved', "FDA nozzle benchmark 72% disagreement (different geometry, not P-01's)"]
- **Failed models:** None recorded
- **Cemetery rules:** SEE R336/m2_discovery_engine/autonomous_discovery_engine.py CEMETERY_RULES
- **Alternative mechanisms rejected:** SEE cemetery entries (P-14, P-17, P-19, P-23, CE-029)
- **Parameter regimes that fail:** SEE R339/g4_p24_vvuq_decision_boundary for P-24 failure envelope
- **Known boundary conditions:** Whether multi-segment advantage survives a TRUE 3D multi-segment mesh (not flow-rate proxy). Implantable flow sensor doesn't exist commercially.

*A buyer should think: 'These people have tried to break their own technology.' That's valuable.*

---

## 10 — Remaining Decisive Question

**The question:** Whether multi-segment advantage survives a TRUE 3D multi-segment mesh (not flow-rate proxy). Implantable flow sensor doesn't exist commercially.

**Decision tree:**
- PASS → Advance toward prototype (see Development Plan Phase 2)
- AMBIGUOUS → Additional experiment required (see Development Plan)
- FAIL → Repair / redesign / terminate (see Failure Record and Cemetery Rules)

- **Pass condition:** Multi-segment peak ICP < single-segment in >=80% of scenarios
- **Fail condition:** Multi-segment shows no advantage over single-segment
- **Ambiguous condition:** CI spans pass/fail threshold → AMBIGUOUS (no silent promotion)

---

## 11 — Development & Experiment Plan

### Phase 1 Bench Validation
- Objective: V0 bench prototype: 4-segment shunt + COTS sensors + Arduino. 30 obstruction scenarios. Measure multi vs single peak ICP.
- Cost: $3-5K (ESTIMATED: COTS components)
- Time: 3-6 months (ESTIMATED)
- Equipment: BUYER_DILIGENCE_REQUIRED
- Expertise: BUYER_DILIGENCE_REQUIRED
- Pass criteria: Multi-segment peak ICP < single-segment in >=80% of scenarios
- Dependencies: None (first phase)

### Phase 2 Prototype
- Objective: Build functional prototype incorporating bench-validated mechanism
- Cost: BUYER_DILIGENCE_REQUIRED
- Time: BUYER_DILIGENCE_REQUIRED
- Equipment: BUYER_DILIGENCE_REQUIRED
- Expertise: BUYER_DILIGENCE_REQUIRED
- Pass criteria: BUYER_DILIGENCE_REQUIRED
- Dependencies: Phase 1 PASS

### Phase 3 Relevant Environment
- Objective: Test in clinically relevant environment (cadaver, animal, or simulated)
- Cost: BUYER_DILIGENCE_REQUIRED
- Time: BUYER_DILIGENCE_REQUIRED
- Dependencies: Phase 2 PASS

### Phase 4 Regulatory Validation
- Objective: Regulatory submission and approval
- Cost: BUYER_DILIGENCE_REQUIRED
- Time: BUYER_DILIGENCE_REQUIRED
- Dependencies: Phase 3 PASS

### Phase 5 Commercial Deployment
- Objective: Commercial launch and post-market surveillance
- Cost: BUYER_DILIGENCE_REQUIRED
- Time: BUYER_DILIGENCE_REQUIRED
- Dependencies: Phase 4 regulatory approval

---

## 12 — Manufacturing & Integration

- Components: BUYER_DILIGENCE_REQUIRED
- Suppliers: BUYER_DILIGENCE_REQUIRED
- Manufacturing process: BUYER_DILIGENCE_REQUIRED
- Tolerances: BUYER_DILIGENCE_REQUIRED — see VVUQ for parameter sensitivity (P-24: R339/g4)
- Scale-up issues: BUYER_DILIGENCE_REQUIRED
- Integration points: HIGH burden — requires multi-segment catheter + flow sensor (not commercially available)
- Software/hardware dependencies: BUYER_DILIGENCE_REQUIRED
- Estimated engineering effort: BUYER_DILIGENCE_REQUIRED
- Unresolved manufacturing risks: BUYER_DILIGENCE_REQUIRED

*If you licensed this tomorrow, what would you actually have to do? This section must be filled during buyer diligence.*

---

## 13 — Regulatory Diligence

- Known regulatory category: PMA required (Class III implantable)
- Known requirements: BUYER_DILIGENCE_REQUIRED
- Unknown requirements: BUYER_DILIGENCE_REQUIRED
- Likely testing: BUYER_DILIGENCE_REQUIRED
- Regulatory dependencies: BUYER_DILIGENCE_REQUIRED
- Specialist review required: Regulatory consultant / FDA pre-submission meeting

*Never claim 'regulatory approved' unless actually approved.*

---

## 14 — IP / Ownership / FTO Diligence

- IP status: BUYER_DILIGENCE_REQUIRED — no patent search performed
- Known disclosures: BUYER_DILIGENCE_REQUIRED
- Known prior art sources: BUYER_DILIGENCE_REQUIRED — see CEREVASC_SLOT5_DISCOVERY for prior art searches
- Ownership: CereVascular (assumed — confirm with CEO)
- Contributors: BUYER_DILIGENCE_REQUIRED
- Third-party technology: BUYER_DILIGENCE_REQUIRED
- License restrictions: UNKNOWN
- Patent search status: NOT_PERFORMED — we are not running a patent court
- FTO status: BUYER_DILIGENCE_REQUIRED — buyer counsel must perform freedom-to-operate analysis
- Counsel review required: Full IP diligence by buyer counsel

*We surface open questions. Buyer counsel performs detailed diligence. We do not render patentability verdicts.*

---

## 15 — Commercialization / Deal Path

**Recommended path:** License to shunt OEM

**Options:**

### LICENSE
- what_is_licensed: The P-01 mechanism, architecture, and supporting evidence package
- field_of_use: BUYER_DILIGENCE_REQUIRED
- exclusivity: BUYER_DILIGENCE_REQUIRED
- consideration: BUYER_DILIGENCE_REQUIRED

### CO_DEVELOP
- what_each_party_contributes: CereVascular: mechanism + evidence. Buyer: manufacturing + clinical + regulatory.
- governance: BUYER_DILIGENCE_REQUIRED

### BUILD
- what_buyer_develops: Full productization from mechanism + evidence package
- estimated_effort: BUYER_DILIGENCE_REQUIRED

### ACQUIRE
- what_assets_transfer: All IP, evidence, models, protocols, know-how
- valuation: BUYER_DILIGENCE_REQUIRED — see WIPO valuation guidance (market/cost/income approaches)

### COMMISSION_EXPERIMENT
- cost: $3-5K (ESTIMATED: COTS components)
- timeline: 3-6 months (ESTIMATED)
- what_it_decides: Whether multi-segment advantage survives a TRUE 3D multi-segment mesh (not flow-rate proxy). Implantable flow sensor doesn't exist commercially.

### REJECT
- evidence_justifying_walking_away: ['Strict dual-invariant FALSIFIED (peak 22>20 mmHg)', '24h survival not achieved', "FDA nozzle benchmark 72% disagreement (different geometry, not P-01's)"]

**Buyer action:** LICENSE — reproduce computation (clone, run svMultiPhysics), then commission V0 bench prototype

---

## Validation (Independent)

- Validator independent from generator: True
- Article XXVI compliance: No self-certification
- Q1 (send without verbal): PASS
- Q2 (identify next step): PASS
- Q3 (facts vs hypotheses): PASS
- Q4 (challenge without trusting): PASS